We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Liquid Biopsy Detects Cancer across Multiple Biomarkers

By LabMedica International staff writers
Posted on 06 Dec 2018
Although biomarker-directed therapy is in its infancy in prostate cancer compared to some other tumor types, there is a great need for predictive biomarker testing, and great interest in noninvasive methods. More...
However, comprehensive analysis of patients' cell-free DNA has been limited to date.

Prostate cancer is the most commonly detected male cancer in Europe and the third major cause of cancer-related death among men. Although the majority of metastatic hormone-naïve prostate cancers (mHNPCs) demonstrate a reliable response to initial androgen deprivation therapy, which targets androgen receptor (AR) signaling, progression to a castration-resistant state is inevitable.

A large international team of scientists led by those at the Karolinska Institute (Stockholm, Sweden) sequenced cell-free DNA from 364 blood samples taken from 217 prostate cancer patients with metastatic, castration-resistant disease, using a combination of targeted and low-pass whole-genome sequencing. Germline DNA was extracted from leftover EDTA blood. In addition, for 340 out of 364 circulating DNA (ctDNA)-analyzed blood samples, an additional blood sample was collected in a CellSave tube and shipped to the GZA Sint-Augustinus for circulating tumor cells (CTC) enumeration within 72 hours on the FDA-cleared CellSearch platform.

The team detected circulating tumor DNA in 86% of samples. They were also able to measure differences in the levels of circulating tumor DNA that corresponded to how many treatments a patient had had. Looking at specific biomarkers, such as the androgen receptor, that have emerged as potential clinical predictors for prostate tumors, the group found for example that the fraction of patients with intra-AR structural variation increased from about 15% during first-line therapy to over 45% in fourth-line treatment. The investigators also calculated the level of microsatellite instability (MSI) in a subset of samples, a measure that is increasingly used in the clinic to identify patients who are eligible for immunotherapies. About 3.8% of the cohort had high MSI based on the circulating DNA analysis.

The authors concluded that ctDNA profiles appear to mirror the genomic landscape of metastatic prostate cancer tissue and may cost-efficiently provide somatic information in clinical trials designed to identify predictive biomarkers. However, intronic sequencing of the interrogated tumor suppressors challenges the ubiquitous focus on coding regions and is vital, together with profiling of synchronous white blood cells, to minimize erroneous assignments which in turn may confound results and impede true associations in clinical trials. The study was published on November 21, 2018, in the journal Genome Medicine.

Related Links:
Karolinska Institute


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.